Stock·NYSE·Healthcare
HCA Healthcare, Inc. (HCA)
- Market cap
- $99.34B
- P/E
- 15.38
- Dividend yield
- 0.67%
- Street target
- $475.50median of 26 analysts
- 52-week range
- $353.99 $556.52
The short version
Where HCA stands today, in four lines, and what CleaRank Financial AI makes of it.
HCA at a glance
HCA Healthcare, Inc. (HCA): Buy, 75/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($426.49 and $444.92).
- Earnings HCA beat estimates in 6 of its last 7 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $38.5M and made no open-market purchases over the last 18 months.
- Valuation P/E of 15.4 against 31.9 for the Healthcare sector: a discount to peers (-52%).
Figures as of October 18, 2026.
CleaRank Financial AI
HCA Healthcare, Inc. (HCA) earns a CleaRank rating of Buy and a model score of 75/100.
Valuation adds the most to that score. The P/E of 15.38 is 51.8% below the sector median, a discount to peers, and the P/S of 1.30 is 61.8% below the sector median. The trend is up, with the price 7.59% above its 50-day average of $426.49 and 3.13% above its 200-day average of $444.92. The price rose 9.35% over the past year.
Only on CleaRank
Figures we compute ourselves from HCA's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $458.84 is 7.6% above the 50-day simple moving average of $426.49.Price above its 200-day average ›
The price is 3.1% above the 200-day simple moving average of $444.92.50-day average above the 200-day ›
The 50-day average ($426.49) is 4.1% below the 200-day average ($444.92), the arrangement of a falling longer-term trend.In the upper half of its 52-week range ›
The price sits at 52% of its 52-week range, between $353.99 and $556.52.
HCA share price
Pick a period: each tab shows how far HCA has moved over it, to the last close.
Today's trading
Where HCA sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
5/5P/E below the sector median ›
The trailing P/E of 15.38 is 51.8% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 1.30 is 61.6% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $6.8B on revenue of $78.0B, a net margin of 8.8%.Beat estimates in most recent reports ›
HCA beat the EPS estimate in 6 of its last 7 reports.Pays a dividend ›
The trailing dividend yield is 0.67%, or $3.06 a share a year.
Key statistics
The headline figures for HCA.
As of October 18, 2026, HCA trades at $458.84, with a market value of $99.34B, a P/E ratio of 15.38 and a dividend yield of 0.67%.
What the numbers say
CleaRank Financial AI's reading of HCA's valuation, growth and risks.
HCA Healthcare, Inc. (HCA) has a trailing P/E of 15.38, which is 51.8% below the Healthcare median of 31.9. The peer comparison on this page puts the P/E at a discount to peers. On sales, HCA trades at 1.30 times, 61.8% below the sector median of 3.4. For scale, the company has a market capitalisation of $99.3B.
With revenue growth of 8.70%, HCA is 0.6 percentage points faster than the sector median of 8.1%. Profitability shows a net margin of 8.77% and an operating margin of 15.16%, with a return on equity of -244.82%, below the sector median of 7.3%. The balance sheet and payout round out the picture, with a trailing dividend yield of 0.67% ($3.06 a share a year).
EPS of $7.59 against an estimate of $7.50 made the July 24, 2026 report a beat of 1.20%. The market agreed: the stock rose 1.94% the following session.
HCA beat the EPS estimate in 6 of its last 7 reports; even so, 1 of those 6 beats was followed by a lower share price the next session. Analysts' average EPS estimate for this fiscal year is $29.48, which would be growth of 4.5%, and $32.01 for next year (growth of 8.6%).
HCA's average daily move is 1.60%. The share price is 17.55% below its 52-week high of $556.52. Over the last 18 months insiders sold $38.5M and made no open-market purchases. Insider sales are often planned in advance or made to cover taxes on vesting shares, so they carry less weight than purchases would.
HCA against the Healthcare sector
How HCA compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: HCA trades at a notable discount to sector peers (-52%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 6, 2025, HCA has gained 28.6% against a gain of 31.6% for XLV.
Performance against XLV
HCA and the Healthcare sector fund over the same days.
Revenue and earnings
How much HCA sells, and how much of it becomes profit.
Revenue growth: Revenue grew 7.1% in FY2025 to $75.6B, from $70.6B a year earlier.
Profit margin: The net margin was 10.3% in FY2025, up from 9.4% the year before.
Profitable: HCA earned $7.8B in FY2025.
Earnings reality check
Did HCA beat what analysts expected, and how did the stock react?
Earnings record: HCA beat the analyst estimate in 6 of the last 7 quarters.
Market reaction: The stock fell in the first session after 1 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Jul 24, 2026after close | $7.50 | $7.59 | +1.20% | +1.94% | +5.34% |
| Apr 24, 2026after close | $7.13 | $7.15 | +0.28% | +3.08% | +0.15% |
| Jan 27, 2026after close | $7.48 | $8.01 | +7.09% | -2.89% | -1.31% |
| Jul 25, 2025after close | $6.32 | $6.84 | +8.23% | +1.86% | +6.77% |
| Apr 25, 2025after close | $5.75 | $6.45 | +12.17% | +1.25% | +6.11% |
| Jan 24, 2025after close | $6.14 | $6.22 | +1.30% | +6.05% | +5.38% |
| Oct 25, 2024after close | $4.98 | $4.90 | -1.61% | -1.91% | -1.75% |
As of October 18, 2026, HCA has beaten the analyst EPS estimate in 6 of its last 7 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on July 24, 2026, came in 1.20% above the estimate and the stock moved +1.94% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 63.1, showing bullish momentum without being overbought.RSI above 50 ›
An RSI of 63.1 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of HCA
The score, the reasoning behind it, and what could move the price next.
HCA Healthcare, Inc. (HCA) keeps an upward trend, priced at $458.84: 7.59% above its 50-day average of $426.49 and 3.13% above its 200-day average of $444.92. The 50-day average sits 4.14% below the 200-day, which shows the recovery has not reached the longer-run averages. Within its 52-week range of $353.99 to $556.52, the price sits at 52%, 17.55% below the high.
The 14-day RSI of 63.1 is in the bullish zone, below the overbought line, and the MACD line is positive. The price is up over each of these periods: 6.60% over the past month, 23.62% over the past three months and 9.35% over the past year. Volume in the last session ran 51.1% above its average, on a day the price fell 2.06%.
Earnings beat ›
The July 24, 2026 report beat the EPS estimate by 1.20%, and the share price rose 1.94% in the first session after it.
Source: Earnings report, July 24, 2026Rating reaffirmed ›
TD Cowen kept its Buy rating on October 12, 2026.
Source: Analyst action, TD Cowen, October 12, 2026
New analyst coverage ›
BMO Capital started coverage at Outperform on September 23, 2026.
Source: Analyst action, BMO Capital, September 23, 2026
- Keep an eye on the two closest levels: the 52-week high at $556.52 above the price, and the 200-day SMA at $444.92 below it.
- The 14-day RSI stands at 63.1, inside the bullish zone, and the MACD line is positive. Readings above 70 or below 30 would signal stretched momentum.
- In the first session after the July 24, 2026 report, the share price climbed 1.94%. Over the last 7 reports, HCA has beaten estimates in 6 of them.
The uptrend rests on HCA staying above its 50-day average at $426.49 and its 200-day average at $444.92; a close below the 200-day would be the first crack in it. On a pullback, the first level the price would meet is the 200-day SMA at $444.92.
HCA's next overhead level is the 52-week high of $556.52. With the RSI in the bullish zone, momentum still supports the move higher.
Technical indicators
Momentum and trend for HCA, from its daily closes.
As of October 18, 2026, with HCA at $458.84, its 14-day RSI is 63.1 (showing bullish momentum without being overbought), its 50-day simple moving average is $426.49 and its 200-day is $444.92.
Calculated by CleaRank on daily closes as of October 18, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What HCA moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 18, 2026, HCA's 1-year correlation of daily returns is +0.14 with S&P 500 (SPY), +0.04 with Nasdaq 100 (QQQ), +0.01 with Bitcoin (BTC) and +0.01 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
15 of 26 analysts rate it a buy or strong buy, 10 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $475.50 is 3.6% above the price.More buy ratings than three months ago ›
15 of 26 rate it a buy now, against 14 of 25 three months ago.
HCA Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 12, 2026 | TD Cowen | Maintains | Buy |
| Oct 7, 2026 | RBC Capital | Maintains | Outperform |
| Sep 23, 2026 | BMO Capital | Initiates | Outperform |
| Sep 18, 2026 | Leerink Partners | Maintains | Outperform |
| Sep 8, 2026 | RBC Capital | Reiterates | Outperform |
| Aug 20, 2026 | JP Morgan | Maintains | Neutral |
As of October 18, 2026, 26 Wall Street analysts cover HCA: 15 rate it a buy or strong buy, 10 a hold and 1 a sell or strong sell. Their 12-month price targets range from $380.00 to $579.00, with a median of $475.50, 3.6% above the price of $458.84.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
HCA trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from HCA's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much HCA tends to move, against the market and on its own.
The long record
HCA's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.60% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 47.8%, from February 2020 to March 2020, regained by November 2020.Most 1-year holds ended higher ›
83% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $60,492, against $41,793 in the S&P 500 (SPY).
HCA Drawdowns & Recovery
As of October 18, 2026, HCA's worst peak-to-trough fall over the last 10 years with dividends reinvested was -47.8% (February 2020 to March 2020); it regained that peak by November 2020, 8 months after the low, and 83% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into HCA in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: HCA beat the S&P 500 over this period: $60,492 against $41,793.
A $10,000 investment in HCA in October 2016 would be worth about $60,492 today with dividends reinvested, compared with about $41,793 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to HCA, and which have not.
Strongest month, July: an average of +7.85%, up in 7 of 10 years.
Weakest month, September: an average of -2.33%, up in 3 of 10 years.
This month, October: has averaged +1.34%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, HCA's strongest calendar month has been July (average +7.85%, up in 7 of 10 years) and its weakest September (average -2.33%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in HCA, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in HCA today could grow to about $26,023 by 2036 in the base case, with a 90th-percentile outcome near $99,762 and a 10th-percentile outcome around $6,788. The simulation models price only; at today's 0.67% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
HCA Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $673 for HCA by 2030 in the base case, from $459 today (1.5x over 4 years). The 10th-percentile path ends near $288. These are outcomes of a Monte Carlo simulation run on HCA's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $330 | $505 | $772 | |
| 2028 | $305 | $556 | $1,013 | |
| 2029 | $293 | $611 | $1,276 | |
| 2030 | $288 | $673 | $1,574 | |
| 2031 | $286 | $740 | $1,914 |
Method: a lognormal simulation of HCA's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
HCA insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: No insider bought HCA shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 18, 2026, HCA insiders reported 8 open-market sales worth $38.5M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| May 7, 2026 | Mike A Marks
Chief Financial Officer
|
Grant | 3.3K | - |
| Apr 28, 2026 | John W Chidsey
Director
|
Grant | 809 | - |
| Apr 28, 2026 | Nancy-Ann M. J.d. Deparle
Director
|
Grant | 509 | - |
| Apr 28, 2026 | Thomas F Frist III
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 1.0K | - |
| Apr 28, 2026 | William R. Frist
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 809 | - |
| Apr 28, 2026 | Hugh F. Johnston
Director
|
Grant | 809 | - |
| Apr 28, 2026 | Michael W Michelson
Director
|
Grant | 925 | - |
| Apr 28, 2026 | Wayne Joseph Riley
Director
|
Grant | 509 | - |
| Apr 28, 2026 | Andrea B Smith
Director
|
Grant | 509 | - |
| Feb 18, 2026 | Michael R. Mcalevey
Officer
|
Sell | 1.7K | $903.5K |
| Feb 13, 2026 | Michael R. Mcalevey
Officer
|
Option | 5.0K | $1.2M |
| Feb 11, 2026 | Jennifer Berres
Officer
|
Sell | 8.0K | $4.1M |
| Feb 11, 2026 | Christopher F Wyatt
Officer
|
Sell | 4.0K | $2.0M |
| Feb 10, 2026 | Jennifer Berres
Officer
|
Grant | 7.1K | - |
| Feb 10, 2026 | Michael S Cuffe
Officer
|
Grant | 9.6K | - |
| Feb 10, 2026 | Jon Mark Foster
Chief Operating Officer
|
Grant | 15.7K | - |
| Feb 10, 2026 | Samuel N Hazen
Chief Executive Officer
|
Grant | 54.9K | - |
| Feb 10, 2026 | Mike A Marks
Chief Financial Officer
|
Grant | 5.0K | - |
| Feb 10, 2026 | Michael R. Mcalevey
Officer
|
Grant | 8.4K | - |
| Feb 10, 2026 | Erica Rossitto
Officer
|
Grant | 1.7K | - |
| Feb 10, 2026 | Christopher F Wyatt
Officer
|
Grant | 3.4K | - |
| Feb 5, 2026 | Jon Mark Foster
Chief Operating Officer
|
Option | 29.3K | $4.1M |
| Feb 5, 2026 | Christopher F Wyatt
Officer
|
Option | 10.7K | $1.5M |
| Feb 3, 2026 | Samuel N Hazen
Chief Executive Officer
|
Sell | 42.9K | $21.5M |
| Feb 3, 2026 | Michael S Cuffe
Officer
|
Sell | 1.5K | $747.1K |
| Feb 3, 2026 | Michael S Cuffe
Officer
|
Grant | 4.1K | - |
| Jan 30, 2026 | Samuel N Hazen
Chief Executive Officer
|
Option | 84.4K | $6.9M |
| Nov 14, 2025 | Samuel N Hazen
Chief Executive Officer
|
Grant | 14.8K | - |
| Nov 5, 2025 | Michael R. Mcalevey
Officer
|
Sell | 3.9K | $1.8M |
| Nov 5, 2025 | Mike A Marks
Chief Financial Officer
|
Grant | 330 | - |
| Nov 3, 2025 | Michael R. Mcalevey
Officer
|
Option | 13.2K | $3.1M |
| Oct 31, 2025 | Samuel N Hazen
Chief Executive Officer
|
Option | 58.1K | $4.0M |
| Sep 8, 2025 | Michael S Cuffe
Officer
|
Sell | 3.8K | $1.6M |
| Sep 4, 2025 | Michael S Cuffe
Officer
|
Option | 10.9K | $1.9M |
| Jul 29, 2025 | John W Chidsey
Director
|
Grant | 496 | - |
| May 13, 2025 | Jon Mark Foster
Officer
|
Sell | 15.7K | $5.8M |
| May 13, 2025 | Jon Mark Foster
Officer
|
Grant | 3.2K | - |
| May 13, 2025 | Samuel N Hazen
Chief Executive Officer
|
Grant | 90.1K | - |
| May 7, 2025 | Mike A Marks
Chief Financial Officer
|
Grant | 935 | - |
| Apr 29, 2025 | Robert Jay Dennis
Director
|
Grant | 1.0K | - |
| Apr 29, 2025 | Nancy-Ann M. J.d. Deparle
Director
|
Grant | 645 | - |
| Apr 29, 2025 | Thomas F Frist III
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 1.3K | - |
| Apr 29, 2025 | William R. Frist
Director and Beneficial Owner of more than 10% of a Class of Security
|
Grant | 1.0K | - |
| Apr 29, 2025 | Hugh F. Johnston
Director
|
Grant | 1.0K | - |
| Apr 29, 2025 | Michael W Michelson
Director
|
Grant | 1.2K | - |
| Apr 29, 2025 | Wayne Joseph Riley
Director
|
Grant | 645 | - |
| Apr 29, 2025 | Andrea B Smith
Director
|
Grant | 645 | - |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 18, 2026.